[{"data":1,"prerenderedAt":165},["ShallowReactive",2],{"drug-nitroprusside":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":44,"contraindications":72,"warnings":82,"renal":89,"monitoring":90,"interactions":91,"review":92,"examples":95,"atc":105,"iran":107,"usApproval":119,"links":125,"populations":139},"nitroprusside",1,{"fa":7,"en":8},"سدیم نیتروپروساید","Sodium nitroprusside","cardiovascular",{"fa":11,"en":12},"گشادکننده مستقیم عروق","Direct vasodilator",[14],{"name":15,"market":16},"Nipride RTU","US",[18,19,20,21],"nipride","nitropress","نیتروپروساید","نیپراید",[23,36],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":31,"refs":32},"vial-200","injection","iv","0.2 mg\u002FmL ready-to-use (= 200 mcg\u002FmL)",{"amount":29,"unit":30,"perVolumeMl":5},200,"mcg",[16],[33],{"source":34,"section":35},"fda-nipride","3",{"id":37,"form":25,"route":26,"label":38,"concentration":39,"markets":41,"refs":42},"vial-500","0.5 mg\u002FmL ready-to-use (= 500 mcg\u002FmL)",{"amount":40,"unit":30,"perVolumeMl":5},500,[16],[43],{"source":34,"section":35},[45],{"id":46,"disease":47,"label":48,"population":51,"type":52,"unit":30,"dose":53,"refs":56,"notes":59},"htn","hypertensive-emergency",{"fa":49,"en":50},"بحران فشار خون، نارسایی حاد قلب، کاهش کنترل‌شده فشار — شروع ۰٫۳ mcg\u002Fkg\u002Fدقیقه، حداکثر ۱۰","Hypertensive crisis, acute heart failure, controlled hypotension — start 0.3 mcg\u002Fkg\u002Fmin, max 10",{},"infusion",{"perKgPerMin":54,"perKgPerMinMax":55},0.3,10,[57],{"source":34,"section":58},"2.2",[60],{"text":61,"refs":64},{"fa":62,"en":63},"پایش مداوم فشار؛ دست‌کم ۵ دقیقه صبر پیش از تغییر. فقط با پمپ حجمی. محلول آبی، سبز یا قرمز روشن مصرف نشود. با حداکثر سرعت، ظرف کمتر از ۱ ساعت ظرفیت سم‌زدایی سیانید پر می‌شود.","Continuous BP monitoring; wait ≥5 min before changing. Volumetric pump only. Do not use blue, green or bright-red solution. At the maximum rate, cyanide buffering capacity is exceeded in under 1 h.",[65,66,68,70],{"source":34,"section":58},{"source":34,"section":67},"2.3",{"source":34,"section":69},"2.1",{"source":34,"section":71},"Boxed Warning",[73],{"id":74,"severity":75,"text":76,"refs":79},"ci","block",{"fa":77,"en":78},"فشار جبرانی (کوآرکتاسیون آئورت، شانت شریانی-وریدی)؛ خونرسانی ناکافی مغز یا بیمار در حال مرگ (ASA 5E)؛ آتروفی عصب بینایی لبر یا آمبلیوپی تنباکو؛ نارسایی حاد قلب با مقاومت عروقی پایین؛ سیلدنافیل، تادالافیل، واردنافیل یا ریوسیگوات.","Compensatory hypertension (aortic coarctation, AV shunting); inadequate cerebral circulation or moribund patients (ASA 5E); Leber’s optic atrophy or tobacco amblyopia; acute heart failure with reduced peripheral resistance; sildenafil, tadalafil, vardenafil or riociguat.",[80],{"source":34,"section":81},"4",[83],{"text":84,"refs":87},{"fa":85,"en":86},"هشدار جعبه‌ای: افت شدید فشار (آسیب ایسکمیک یا مرگ)؛ مسمومیت سیانید وابسته به دوز — مدت انفوزیون با حداکثر سرعت محدود شود.","Boxed warning: precipitous hypotension (ischaemic injury or death); dose-related, potentially lethal cyanide toxicity — limit time at the maximum rate.",[88],{"source":34,"section":71},[],[],[],{"status":93,"reviewer":94,"date":94},"unverified",null,[96],{"regimen":46,"formulation":24,"input":97,"expect":100},{"ageYears":98,"weightKg":99},60,70,{"perMin":101,"mlPerHour":102,"upperPerMin":103,"upperMlPerHour":104},21,6.3,700,210,[106],"C02DD01",{"status":108,"forms":109,"refs":114},"registered",[110],{"code":111,"en":112,"fa":113},"00916","NITROPRUSSIDE SODIUM 50MG AMP","آمپول نیتروپروسساید سدیم ۵۰ میلی‌گرم",[115],{"source":116,"section":117,"url":118},"darooyab-generic","G-1884\u002FSodium-Nitroprusside","https:\u002F\u002Fwww.darooyab.ir\u002FG-1884\u002FSodium-Nitroprusside",{"kind":120,"refs":121,"id":124},"NDA",[122],{"source":34,"section":123},"SPL approval \u002F marketing category","NDA209387",[126,129,133,136],{"kind":127,"url":128,"label":124},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=209387",{"kind":130,"url":131,"label":132},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5acf0836-93ff-4064-b888-3f560e8a558d","FDA Nipride RTU",{"kind":134,"url":135,"label":106},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C02DD01",{"kind":137,"url":118,"label":138},"darooyab","Sodium-Nitroprusside",{"pregnancy":140,"lactation":149,"pediatric":157},{"level":141,"text":142,"quote":145,"refs":146},"caution",{"fa":143,"en":144},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Based on animal data and mechanism of action, sodium nitroprusside may lead to cyanide exposure and potential adverse effects in the fetus [see Clinical Pharmacology ( 12.3 ) and Clinical Considerations] .",[147],{"source":34,"section":148},"8.1",{"level":141,"text":150,"quote":153,"refs":154},{"fa":151,"en":152},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information about the presence of sodium nitroprusside in human milk, the effects on the breastfed infant, or the effects on milk production.",[155],{"source":34,"section":156},"8.2",{"level":141,"text":158,"quote":161,"refs":162},{"fa":159,"en":160},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Efficacy in the pediatric population was established based on adult trials and supported by the dose-ranging trial (Study 1) and an open label trial of at least 12 hour infusion at a rate that achieved adequate MAP control (Study 2) with pediatric patients on sodium nitroprusside.",[163],{"source":34,"section":164},"8.4",1792191566818]